Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH-Reference-Cited by-同舟云学术

Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH

Published:2017-06-14 Issue:12 Volume:37 Page:1887-1896
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

Vilar-Gomez Eduardo¹²^ORCID,Calzadilla-Bertot Luis¹³,Friedman Scott L.⁴,Gra-Oramas Bienvenido⁵,Gonzalez-Fabian Licet⁵,Lazo-del Vallin Sacha⁶,Diago Moises⁷,Adams Leon A.³

Affiliation:

1. Department of Hepatology; National Institute of Gastroenterology; Havana Cuba

2. Division of Gastroenterology and Hepatology; Indiana University School of Medicine; Indiana USA

3. School of Medicine and Pharmacology; The University of Western Australia; Nedlands Australia

4. Division of Liver Diseases; Icahn School of Medicine at Mount Sinai; New York USA

5. Department of Pathology; National Institute of Gastroenterology; Havana Cuba

6. Department of Radiology; National Institute of Gastroenterology; Havana Cuba

7. Liver Unit; Department of Gastroenterology; Valencia University General Hospital; Valencia Spain

Funder

National Institute of Gastroenterology

Ministry of Health

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.13480/fullpdf

Reference34 articles.

1. Liver biopsy;Rockey;Hepatology,2009

2. Sampling variability of liver biopsy in nonalcoholic fatty liver disease;Ratziu;Gastroenterology,2005

3. Effects of liver biopsy sample length and number of readings on sampling variability in nonalcoholic Fatty liver disease;Vuppalanchi;Clin Gastroenterol Hepatol,2009

4. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology;Chalasani;Gastroenterology,2012

5. Non-invasive tests for evaluation of liver disease severity and prognosis;EASL-ALEH Clinical Practice Guidelines;J Hepatol,2015

Cited by 57 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effects of luseogliflozin on suspected MASLD in patients with diabetes: a pooled meta-analysis of phase III clinical trials;Journal of Gastroenterology;2024-07-26

2. Deep learning for predicting fibrotic progression risk in diabetic individuals with metabolic dysfunction-associated steatotic liver disease initially free of hepatic fibrosis;Heliyon;2024-07

3. Risk factors for fibrosis progression in non-alcoholic steatohepatitis: Analysis of the European cohort in the real-world GAIN study;Gastroenterología y Hepatología (English Edition);2024-05

4. Performance of non-invasive tests for liver fibrosis resolution after bariatric surgery;Metabolism;2024-04

5. AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis;Hepatology;2024-03-15